• DelMar’s New Chemotherapeutic VAL-083 Shows Promise in TKI-resistant NSCLC
  • Opdivo More Than Tripled 5-Year Survival Rates in NSCLC Patients in Phase 1 Study
  • OncoMed Ends Enrollment in Demcizumab Trials, Including Lung Cancer Studies
  • Genentech’s Alecensa Superior to Xalkori in Newly Diagnosed ALK+ Advanced NSCLC Patients
  • Alecensa Improves Progression-Free Survival in Certain Lung Cancer Patients
  • Screening Initiative in Georgia Finds Twice the Lung Cancer Rate of Previous Efforts
  • Phase 1 Study of RET Inhibitor in Lung Cancer, Other Tumors Doses First Patient
  • Mobile Unit Begins Lung Cancer Screening in Rural Areas of Carolinas
  • Phase 2 Trial of TG4010, Opdivo Combo for NSCLC Gets Underway
  • Lung Cancer Is Underdiagnosed in Metastatic Kidney Cancer Patients, Study Suggests
  • Get Screened or Not? Counseling, Professional Consultations Help People at High Risk Decide
  • Statins Don’t Help Small-cell Lung Cancer Patients Who Get Chemotherapy, Study Suggests